Evidence map›Paper›PMID 39567938›Full record

ReviewBMC neurology2024

Novel TECPR2 variant in two cases of hereditary sensory and autonomic neuropathy type 9: insights from genetic characterization and comprehensive literature review.

Aysan Moeinafshar, Sahand Tehrani Fateh, Farzad Hashemi-Gorji, Parvaneh Karimzadeh, Elham Gholibeglou, Masoumeh Rostami, Hossein Sadeghi, Mohammad Miryounesi, Mohammad-Reza Ghasemi

Abstract readCase ReportsReview
In one paragraph

Review in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aysan MoeinafsharCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-8944-4123
Sahand Tehrani FatehCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0002-8903-2713
Farzad Hashemi-GorjiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-9996-9406
Parvaneh KarimzadehPediatric Neurology Department, School of Medicine, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-6302-9973
Elham GholibeglouDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Masoumeh RostamiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein SadeghiDepartment of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-9599-6151
Mohammad MiryounesiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran. miryounesi@gmail.com.ORCID http://orcid.org/0000-0003-4705-3794
Mohammad-Reza GhasemiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ghasemimr891@gmail.com.ORCID http://orcid.org/0000-0002-3183-5495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHereditary sensory and autonomic neuropathy type 9 (HSAN9) is a rare genetic disorder caused by genetic alterations in the TECPR2 locus and is characterized by developmental and intellectual disability, respiratory dysfunction, gastroesophageal reflux disease (GERD), and sensory and autonomic dysfunction, which are shared among the HSAN family.

methodsWhole-exome sequencing (WES) was performed on samples from both probands, and the relevant genetic variants were confirmed in their families using Sanger sequencing. Additionally, a comprehensive literature review was conducted on previously reported cases of HSAN9, and the clinical and genetic data were assessed to provide insight into the genetic and clinical characteristics of the disease.

resultsWe identified two new cases of HSAN9 with a shared novel variant of TECPR2 (NM_014844.5), c.1568del: p.Ser523PhefsTer12, classified as pathogenic according to ACMG guidelines. The probands showed characteristics of GERD, respiratory dysfunction, gait abnormalities, and developmental and speech delay, and both cases were deceased as a result of severe respiratory infection. The results of the literature review included 34 cases from 9 studies, revealing a wide range of genetic and clinical characteristics.

conclusionsOur study identified two new cases of HSAN9 with a novel variant in TECPR2, confirmed by WES. The clinical characteristics of the patients as well as the conduction of a comprehensive literature review are crucial in the early diagnosis and management of the disease and establishment of genotype-phenotype correlations.

Indexed as

Hereditary Sensory and Autonomic NeuropathiesNerve Tissue ProteinsCarrier ProteinsChildChild, PreschoolExome SequencingFemaleHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsPedigreeCarrier ProteinsIntracellular Signaling Peptides and ProteinsMembrane ProteinsNerve Tissue ProteinsRETREG1 protein, humanTECPR2 protein, humanHereditary sensory and autonomic neuropathyHereditary sensory and autonomic neuropathy type 9HSAN9TECPR2Whole-exome sequencing (WES)

Identifiers

PMID39567938
PMCPMC11577655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.